Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
Cancer scientists in Britain are launching what they call the world's first "Darwinian" drug development program in a bid to get ahead of cancer's ability to become resistant to even the newest treatments and recur in many patients.The first, known as "evolutionary herding," involves selecting an initial specific treatment that forces cancer cells to adapt in a way that makes them highly susceptible to a second drug, or pushes them into an evolutionary dead end.The second will explore a possible new class of drugs to target cancer's ability to evolve and become resistant to treatment. Researchers hope a new class of APOBEC inhibitors could be developed and given alongside targeted cancer treatments to try and keep cancer at bay for much longer.
FOLLOW THIS ARTICLE